SLC5A2 and diabetes mellitus: The DAPA-HF trial and cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced) trial demonstrated that among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or cardiovascular death was lower in those who received SGLT2 inhibitors than in those who received the placebo, regardless of the presence or absence of diabetes [7,88].